Morris Stephen, Patel Nishma V, Dobson Joanna, Featherstone Roland L, Richards Toby, Luengo-Fernandez Ramon, Rothwell Peter M, Brown Martin M
Department of Applied Health Research, University College London, London, UK
Department of Applied Health Research, University College London, London, UK.
Int J Stroke. 2016 Jun;11(4):446-53. doi: 10.1177/1747493016632237. Epub 2016 Feb 15.
The International Carotid Stenting Study was a multicenter randomized trial in which patients with symptomatic carotid artery stenosis were randomly allocated to treatment by carotid stenting or endarterectomy. Economic evidence comparing these treatments is limited and inconsistent.
We compared the cost-effectiveness of stenting versus endarterectomy using International Carotid Stenting Study data.
We performed a cost-utility analysis estimating mean costs and quality-adjusted life years per patient for both treatments over a five-year time horizon based on resource use data and utility values collected in the trial. Costs of managing stroke events were estimated using individual patient data from a UK population-based study (Oxford Vascular Study).
Mean costs per patient (95% CI) were US$10,477 ($9669 to $11,285) in the stenting group (N = 853) and $9669 ($8835 to $10,504) in the endarterectomy group (N = 857). There were no differences in mean quality-adjusted life years per patient (3.247 (3.160 to 3.333) and 3.228 (3.150 to 3.306), respectively). There were no differences in adjusted costs between groups (mean incremental costs for stenting versus endarterectomy $736 (95% CI -$353 to $1826)) or adjusted outcomes (mean quality-adjusted life years gained -0.010 (95% CI -0.117 to 0.097)). The incremental net monetary benefit for stenting versus endarterectomy was not significantly different from zero at the maximum willingness to pay for a quality-adjusted life year commonly used in the UK. Sensitivity analyses showed little uncertainty in these findings.
Economic considerations should not affect whether patients with symptomatic carotid stenosis undergo stenting or endarterectomy.
国际颈动脉支架置入研究是一项多中心随机试验,有症状的颈动脉狭窄患者被随机分配接受颈动脉支架置入术或动脉内膜切除术治疗。比较这些治疗方法的经济学证据有限且不一致。
我们使用国际颈动脉支架置入研究的数据比较了支架置入术与动脉内膜切除术的成本效益。
我们进行了一项成本效用分析,根据试验中收集的资源使用数据和效用值,估计了两种治疗方法在五年时间范围内每位患者的平均成本和质量调整生命年。使用来自英国一项基于人群的研究(牛津血管研究)的个体患者数据估计中风事件的管理成本。
支架置入组(N = 853)每位患者的平均成本(95% CI)为10477美元(9669美元至11285美元),动脉内膜切除术组(N = 857)为9669美元(8835美元至10504美元)。每位患者的平均质量调整生命年无差异(分别为3.247(3.160至3.333)和3.228(3.150至3.306))。两组之间的调整成本无差异(支架置入术与动脉内膜切除术的平均增量成本为736美元(95% CI -353美元至1826美元))或调整结局(获得的平均质量调整生命年为-0.010(95% CI -0.117至0.097))。在英国常用的为一个质量调整生命年支付的最大意愿下,支架置入术与动脉内膜切除术的增量净货币效益与零无显著差异。敏感性分析表明这些结果几乎没有不确定性。
经济因素不应影响有症状的颈动脉狭窄患者接受支架置入术还是动脉内膜切除术。